WALTHAM, Mass.--(BUSINESS WIRE)--
Thermo Fisher Scientific (NYSE:TMO), the world leader in serving
science, today announced that it has completed the sale of its cell
culture (sera and media), gene modulation and magnetic beads businesses
to GE Healthcare, a unit of General Electric Company (NYSE: GE), for
$1.065 billion. The businesses will become part of GE Healthcare’s Life
The combined revenue of the three businesses was $250 million in 2013.
Thermo Fisher committed to sell these businesses to address regulatory
concerns related to its acquisition of Life Technologies Corporation,
which was completed on February 3, 2014.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE:TMO) is the world leader in serving
science, with revenues of $17 billion and 50,000 employees in 50
countries. Our mission is to enable our customers to make the world
healthier, cleaner and safer. We help our customers accelerate life
sciences research, solve complex analytical challenges, improve patient
diagnostics and increase laboratory productivity. Our four premier
brands – Thermo Scientific, Life Technologies, Fisher Scientific and
Unity Lab Services – offer an unmatched combination of innovative
technologies, purchasing convenience and comprehensive support. For more
information, please visit www.thermofisher.com.
Source: Thermo Fisher Scientific Inc.